A Study of TEV-56286 in Healthy Volunteers
This study is testing a new drug called TEV-56286 in healthy volunteers. The main goal is to understand how your body handles TEV-56286 at different doses – how it's absorbed, distributed, and removed. Researchers also want to see if TEV-56286 is safe and well-tolerated. To join, you need to be a healthy adult between 18 and 60 years old, with a specific body weight and body mass index (BMI). The study will measure how much of the drug is in your blood over a few days after you take it. This information helps researchers learn more about TEV-56286 before it might be tested in people with specific conditions. The study is currently recruiting 60 participants.
- Study design
- This is an interventional study involving 60 healthy volunteers. Participants will receive TEV-56286 orally at different doses.
- What's involved
- If you participate, you would have a screening period of up to 45 days, a 4-day stay in a clinic, and a follow-up visit about 8 days after leaving the clinic. The total time commitment for Part 1 is approximately 58 days.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will have a follow-up visit 8 +/- 1 days after being discharged from the clinical unit.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT07674940
A Trial to Assess TEV-56286 at Different Doses in Healthy Participants
Recruiting
PHASE1Ages 18–60InterventionalTeva Branded Pharmaceutical Products R&D LLC
~60 participants
Updated 2026-07-14 on ClinicalTrials.gov
What's tested:TEV-56286 Dose ATEV-56286 Dose BTEV-56286 Dose CTEV-56286 Dose DTEV-56286 Dose EPlacebo
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
SAD: Time to maximum observed plasma drug concentration (tmax) of TEV-56286
Measured over Day 1 to Day 3
+7 more outcomes measured
Conditions
Where it's being run
1 sites across 1 statesFlorida1
Study leadership
- Teva Medical Expert, MD · STUDY_DIRECTOR · Teva Branded Pharmaceutical Products R&D LLC
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Participant is a healthy male or female with a body weight of ≥50 kg for males and ≥45 kg for females, and body mass index (BMI) of 18.5 to 32.0 kg/m2 inclusive.
Participant is 18 to 60 years of age inclusive, at the time of signing the informed consent form (ICF).
Female participants are eligible to participate if she is not pregnant or breastfeeding, and 1 of the following conditions applies:
A woman of non-child bearing potential (WONCBP) as defined: Female participants who are either surgically (documented hysterectomy, bilateral oophorectomy, or bilateral salpingectomy) or congenitally sterile, or at least 1 year postmenopausal (no menses for at least 12 months without an alternative medical cause plus an increased concentration of follicle stimulating hormone \[FSH\] within the menopausal range in women not using hormonal contraception or hormonal replacement therapy).
A woman of childbearing potential (WOCBP) and using a contraceptive method that is highly effective (with a failure rate of \<1% per year), used consistently and correctly. The acceptable contraceptive regimen in this trial is: non-hormonal intrauterine device (IUD) used for at least 2 consecutive months prior to dosing and willing to continue until at least 28 days after last dose of investigational medicinal product (IMP). A WOCBP must have a negative highly sensitive serum pregnancy test within 24 hours before the first dose of IMP. The participant must be excluded from participation if the serum pregnancy result is positive.
Male participants are eligible to participate if they are azoospermic (vasectomized or due to a medical cause) or, alternatively, agree to the following during the trial period, from admission (day -1) and for at least 28 days after last dose of IMP.
EITHER be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent.
OR must agree to use contraception/barrier as detailed below:
Agree to use a male condom with female partner using an additional highly effective contraceptive method with a failure rate of \<1% per year when having sexual intercourse with a WOCBP who is not currently pregnant.
Agree to use a male condom when having sexual intercourse with a pregnant partner.
Exclusion
Participant presents with or has a history of clinically significant diseases of the renal, hepatic, gastrointestinal, cardiovascular, musculoskeletal system, or presence/history of clinically significant immunological, endocrine, metabolic diseases, neurological, psychiatric, or immunological disorder(s), or a history of any illness that, in the opinion of the Principal Investigator, might pose additional risk to the participant by participation in the trial or confound the results of the trial.
Participant presents with a major trauma or surgery during the 60 days prior to screening or at any time between screening and the first dose of IMP, or surgery scheduled during the trial including follow-up period.
The participant has a history of any malignant disease (except for treated and cured skin basal cell carcinoma at least 12 months prior to screening).
Participant has a known drug hypersensitivity reaction to the active component of IMP, or one of its excipients, or any compound listed as being present in a trial formulation.
Participant has a personal or family history of arrhythmia, long QT syndrome, or sudden unexplained death in a first-degree relative before the age of 40; or personal history of syncope, myocardial infarction, cerebrovascular accident, or previous treatment for high blood pressure (BP).
Participant has an alkaline phosphatase (ALP), alanine aminotransferase (ALT), or aspartate aminotransferase (AST) \>1.5 × upper limit of normal (ULN).
Participant has a history of alcohol, drug, or any other substance dependence (with the exception of nicotine or caffeine) as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (American Psychiatric Association 2013) or are unwilling to comply with the restricted food or beverages during the trial.
Participant is a current smoker, has smoked in the last 6 months, is planning to start smoking during the trial, uses tobacco, or uses other nicotine-containing products (eg, snuff, nicotine patch, nicotine chewing gum, mock cigarettes, e-cigarettes, vaping devices, inhalers), or has a positive urine cotinine test.
What this trial measures
- SAD: Time to maximum observed plasma drug concentration (tmax) of TEV-56286Day 1 to Day 3
- SAD: Maximum observed plasma concentration (Cmax) of TEV-56286Day 1 to Day 3
- SAD: Area Under the Plasma Drug Concentration-Time Curve from Time 0 to the Time of the Last Measurable Concentration (AUC0-t) of TEV-56286Day 1 to Day 3
- SAD: Area Under the Plasma Drug Concentration-Time Curve from Time 0 to Infinity (AUC0-inf) of TEV-56286Day 1 to Day 3
- MD: tmax of TEV-56286Day 7 to Day 9
- MD: Cmax of TEV-56286Day 7 to Day 9
- MD: AUC0-t of TEV-56286Day 7 to Day 9
- MD: Area Under the Plasma Drug Concentration-Time Curve for the Defined Interval Between Doses (AUC0-tau) of TEV-56286Day 7 to Day 8